DK1330244T3 - Præparater der omfatter modafinilforbindelser - Google Patents

Præparater der omfatter modafinilforbindelser

Info

Publication number
DK1330244T3
DK1330244T3 DK01979747T DK01979747T DK1330244T3 DK 1330244 T3 DK1330244 T3 DK 1330244T3 DK 01979747 T DK01979747 T DK 01979747T DK 01979747 T DK01979747 T DK 01979747T DK 1330244 T3 DK1330244 T3 DK 1330244T3
Authority
DK
Denmark
Prior art keywords
compositions
modafinil compounds
modafinil
compounds
particles
Prior art date
Application number
DK01979747T
Other languages
English (en)
Inventor
Martin J Jacobs
Bradley T Mcintyre
Piyush R Patel
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of DK1330244T3 publication Critical patent/DK1330244T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK01979747T 2000-10-11 2001-10-11 Præparater der omfatter modafinilforbindelser DK1330244T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23949000P 2000-10-11 2000-10-11
US64082401A 2001-10-10 2001-10-10
PCT/US2001/031904 WO2002030414A1 (en) 2000-10-11 2001-10-11 Compositions comprising modafinil compounds

Publications (1)

Publication Number Publication Date
DK1330244T3 true DK1330244T3 (da) 2009-02-16

Family

ID=26932616

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01979747T DK1330244T3 (da) 2000-10-11 2001-10-11 Præparater der omfatter modafinilforbindelser

Country Status (14)

Country Link
EP (1) EP1330244B1 (da)
JP (1) JP4593074B2 (da)
AT (1) ATE417608T1 (da)
AU (1) AU1167702A (da)
BR (1) BR0114814A (da)
CY (1) CY1110061T1 (da)
CZ (1) CZ306618B6 (da)
DE (1) DE60137069D1 (da)
DK (1) DK1330244T3 (da)
ES (1) ES2317943T3 (da)
HK (1) HK1054688A1 (da)
NZ (1) NZ525236A (da)
PT (1) PT1330244E (da)
WO (1) WO2002030414A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US7229644B2 (en) 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
EP1526842A1 (en) * 2002-07-25 2005-05-04 Ranbaxy Laboratories, Ltd. Processes for the preparation of oral dosage formulations of modafinil
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
MXPA05008088A (es) 2003-02-24 2005-09-21 Mallinckrodt Inc Proceso mejorado para preparar benzhidril tioacetamida.
CN101031290B (zh) * 2003-09-18 2011-09-21 赛福伦公司 改良释放的莫达非尼药物组合物
EP2292213A1 (en) * 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
BRPI0714173A2 (pt) * 2006-07-12 2012-12-25 Elan Pharma Int Ltd composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem
MX340819B (es) 2010-06-29 2016-07-26 Poniard Pharmaceuticals Inc * Formulacion oral de inhibidores de quinasa.
EP2588476A4 (en) 2010-06-30 2014-07-23 Verastem Inc SYNTHESIS AND USE OF KINASE INHIBITORS
FR2987267B1 (fr) * 2012-02-28 2015-01-16 Debregeas Et Associes Pharma Application du modafinil dans le traitement de substitution des cacainomanes
WO2018060843A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Surfactant systems for crystallization of organic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04164024A (ja) * 1990-10-29 1992-06-09 Sankyo Co Ltd 医薬物質含有自己乳化型脂肪乳剤組成物の製造方法
FR2702968B1 (fr) * 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
FR2706767B1 (da) * 1993-06-22 1995-09-08 Lafon Labor
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) * 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
JP2002513750A (ja) * 1998-05-07 2002-05-14 エラン コーポレーシヨン ピーエルシー 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム
CA2360418C (en) * 1999-01-12 2009-05-26 Steven William Booth Spheronised self-emulsifying system for hydrophobic and water-sensitive agents
DK1309547T3 (da) * 2000-07-27 2007-05-21 Teva Pharma Krystallinsk og ren modafinil og fremgangsmåde til fremstilling af samme

Also Published As

Publication number Publication date
AU1167702A (en) 2002-04-22
WO2002030414A1 (en) 2002-04-18
EP1330244A1 (en) 2003-07-30
ES2317943T3 (es) 2009-05-01
CZ306618B6 (cs) 2017-04-05
BR0114814A (pt) 2005-01-25
DE60137069D1 (de) 2009-01-29
CY1110061T1 (el) 2015-01-14
ATE417608T1 (de) 2009-01-15
NZ525236A (en) 2004-12-24
JP4593074B2 (ja) 2010-12-08
PT1330244E (pt) 2009-01-27
CZ20031020A3 (en) 2004-03-17
HK1054688A1 (en) 2003-12-12
JP2004517052A (ja) 2004-06-10
EP1330244B1 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
CY1110061T1 (el) Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης
ATE340844T1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
MXPA03005505A (es) Compuesto modafinilo y mezclas de ciclodextrina.
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
ME01222B (me) Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera
DE60106954D1 (de) Resorcin-derivate
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
SE0301653D0 (sv) Novel compounds
ATE445389T1 (de) Liposomale glucocorticoide
HK1057336A1 (en) Pharmaceutical solutions of modafinil compounds
DE60125945D1 (de) Nasenspüler und dessen auslassstück
WO2003066597A3 (en) Guanidino compounds
BG66081B1 (bg) Състави, съдържащи модафинилни съединения
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
SI1532141T1 (sl) 2-pirolidin-2-il-(1,3,4)-oksadiazolni derivati in njihova uporaba kot antidepresivi
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE391489T1 (de) Haarbehandlungszusammensetzungen
PT1373249E (pt) Derivados de imidazolidina, sua preparacao e sua utilizacao como agente anti-inflamatorio
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks
EA200400764A1 (ru) 1,3-диарилпроп-2-ен-1-оны, композиция на их основе и применение
RS52038B (en) USE OF 7-BUTOXYIMINOMETHYLAMPTOTECIN FOR THE TREATMENT OF NON-PLASMA NEOPLASMS
DE602004012759D1 (de) Behandlung von fibrosen
DE50310743D1 (de) Wässrige formulierungen von (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4- trifluorbutan-1-sulfonat
DK1257538T3 (da) 9-alkylamino-1-nitroacridin-derivater